COFCO Biotechnology Co., Ltd. (SHE:000930)
China · Delayed Price · Currency is CNY 5.19
-0.15 (-2.81%)
May 21, 2026, 3:04 PM CST
COFCO Biotechnology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 16,737 | 17,243 | 19,776 | 20,064 | 19,619 | 23,560 |
Other Revenue | 268.5 | 268.5 | 277.71 | 314.46 | 299.42 | - |
| 17,005 | 17,512 | 20,053 | 20,379 | 19,918 | 23,560 | |
Revenue Growth (YoY) | -13.71% | -12.68% | -1.60% | 2.31% | -15.46% | 18.33% |
Cost of Revenue | 16,125 | 16,499 | 18,908 | 19,798 | 17,837 | 21,122 |
Gross Profit | 880.18 | 1,013 | 1,146 | 581.4 | 2,081 | 2,437 |
Selling, General & Admin | 756.37 | 747.69 | 826.35 | 789.39 | 807.17 | 814.69 |
Research & Development | 123.47 | 159.96 | 128.83 | 165.28 | 132.86 | 119.28 |
Other Operating Expenses | 90.3 | 91.68 | 79.41 | 46.61 | -386.92 | -181.36 |
Operating Expenses | 973.1 | 1,001 | 1,071 | 1,001 | 553.32 | 752.82 |
Operating Income | -92.91 | 11.94 | 75.16 | -419.74 | 1,527 | 1,684 |
Interest Expense | -81.89 | -85.74 | -104.86 | -112.78 | -87.12 | -157.79 |
Interest & Investment Income | 32.93 | 64.58 | 70.96 | 38.77 | 16.24 | 55.51 |
Currency Exchange Gain (Loss) | -35.95 | -35.95 | -1.36 | 10.85 | 65.92 | -1.22 |
Other Non Operating Income (Expenses) | 9.09 | 9.81 | 10.73 | -6.76 | -15.06 | 15.08 |
EBT Excluding Unusual Items | -168.74 | -35.36 | 50.62 | -489.66 | 1,507 | 1,596 |
Gain (Loss) on Sale of Investments | -46.01 | -1.22 | -8.13 | -32.93 | -4.26 | 1.86 |
Gain (Loss) on Sale of Assets | 60.12 | 60.1 | -0.15 | 1.16 | -145.82 | -203.22 |
Asset Writedown | -42.84 | -44.19 | -2.27 | -54.45 | -13.3 | -21.48 |
Other Unusual Items | 75.25 | 75.25 | 58.31 | -0.24 | 5.25 | -5.18 |
Pretax Income | -94.24 | 82.56 | 129.4 | -542.54 | 1,360 | 1,377 |
Income Tax Expense | 25.35 | 36.33 | 83.7 | 73.75 | 299.28 | 247.88 |
Earnings From Continuing Operations | -119.58 | 46.23 | 45.7 | -616.29 | 1,061 | 1,130 |
Minority Interest in Earnings | -4.02 | -7.86 | -20.57 | 14.66 | -2.08 | 0.09 |
Net Income | -123.61 | 38.37 | 25.13 | -601.63 | 1,059 | 1,130 |
Net Income to Common | -123.61 | 38.37 | 25.13 | -601.63 | 1,059 | 1,130 |
Net Income Growth | - | 52.68% | - | - | -6.29% | 90.45% |
Shares Outstanding (Basic) | 1,853 | 1,854 | 1,861 | 1,842 | 1,857 | 1,844 |
Shares Outstanding (Diluted) | 1,853 | 1,854 | 1,861 | 1,842 | 1,857 | 1,849 |
Shares Change (YoY) | -0.53% | -0.43% | 1.08% | -0.85% | 0.45% | -0.18% |
EPS (Basic) | -0.07 | 0.02 | 0.01 | -0.33 | 0.57 | 0.61 |
EPS (Diluted) | -0.07 | 0.02 | 0.01 | -0.33 | 0.57 | 0.61 |
EPS Growth | - | 53.33% | - | - | -6.71% | 90.79% |
Free Cash Flow | 433.97 | 1,174 | -327.49 | 1,323 | 142.66 | 3,732 |
Free Cash Flow Per Share | 0.23 | 0.63 | -0.18 | 0.72 | 0.08 | 2.02 |
Dividend Per Share | 0.030 | 0.030 | - | - | 0.570 | 0.245 |
Dividend Growth | - | - | - | - | 132.65% | 276.92% |
Gross Margin | 5.18% | 5.78% | 5.71% | 2.85% | 10.45% | 10.35% |
Operating Margin | -0.55% | 0.07% | 0.38% | -2.06% | 7.67% | 7.15% |
Profit Margin | -0.73% | 0.22% | 0.13% | -2.95% | 5.31% | 4.79% |
Free Cash Flow Margin | 2.55% | 6.70% | -1.63% | 6.49% | 0.72% | 15.84% |
EBITDA | 401.8 | 504.94 | 561.29 | 47.11 | 1,967 | 2,119 |
EBITDA Margin | 2.36% | 2.88% | 2.80% | 0.23% | 9.88% | 9.00% |
D&A For EBITDA | 494.72 | 493 | 486.14 | 466.84 | 439.53 | 434.94 |
EBIT | -92.91 | 11.94 | 75.16 | -419.74 | 1,527 | 1,684 |
EBIT Margin | -0.55% | 0.07% | 0.38% | -2.06% | 7.67% | 7.15% |
Effective Tax Rate | - | 44.01% | 64.68% | - | 22.01% | 18.00% |
Revenue as Reported | 17,005 | 17,512 | 20,053 | 20,379 | 19,918 | 23,560 |
Advertising Expenses | - | 0.56 | 0.44 | 3.04 | 2.81 | 2.68 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.